NCT05953402
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
Recruiting
Not specifiedAll AgesObservationalBristol-Myers Squibb
~1,182 participants
Updated 2026-06-15 on ClinicalTrials.gov
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Event rate of Major Congenital Malformations (MCM)
Measured over Up to 12 months
Conditions
Where it's being run
1 sites across 1 statesNorth Carolina1
Study leadership
- Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Currently or recently pregnant
Diagnosis of UC
Resident of country where ozanimod is prescribed for the treatment of UC
Exclusion
Exposure to other S1P therapies at any time during pregnancy
What this trial measures
- Event rate of Major Congenital Malformations (MCM)Up to 12 months